Lonvoguran Ziclumeran Shows Strong Phase 3 Efficacy for Hereditary Angioedema

Intellia Therapeutics has announced further positive data from its Phase 3 HAELO trial for lonvoguran ziclumeran, a treatment for hereditary angioedema. The results, also published in The New England Journal of Medicine, indicated a substantial 87% reduction in monthly HAE attacks. This promising outcome, coupled with a favorable safety profile, suggests a significant advancement for patients with this condition.